Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a topoisomerase I inhibitor; it binds to the DNA‑topoisomerase I complex, preventing the re‑ligation step of DNA replication, which leads to accumulation of single‑strand breaks, inhibition of transcription, and ultimately tumor cell death.

The specific dose and schedule are determined by the treating oncologist based on patient factors such as body surface area, disease status, and prior therapy; clinicians follow established oncology guidelines to calculate the appropriate intravenous infusion.

Irinotecan is classified as contraindicated in pregnancy because it may cause fetal harm, and it is not recommended for breastfeeding mothers as it can be excreted in milk; women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the Irinotecan Accord product page at gnhindia.com, specifying the required quantity; GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with other agents such as oxaliplatin‑based regimens, irinotecan offers a distinct mechanism as a topoisomerase I inhibitor and is often used in second‑line therapy; efficacy and safety profiles differ, and selection depends on prior treatment exposure, toxicity tolerance and molecular characteristics of the tumor.

Irinotecan Accord should be stored refrigerated at 2–8 °C, protected from light, and must not be frozen or shaken; the product should be kept in its original packaging until ready for preparation and administration.

The drug is supplied as an injectable solution for intravenous infusion; it is typically diluted in an appropriate carrier fluid and administered over a prescribed period, usually 30–90 minutes, under the supervision of qualified healthcare professionals in a clinical setting.

The most critical adverse events include severe neutropenia with fever, life‑threatening diarrhea (colitis), hepatotoxicity, and rare allergic reactions such as anaphylaxis; patients should be closely monitored for signs of infection, gastrointestinal toxicity and liver dysfunction throughout therapy.

Irinotecan is contraindicated in patients with known hypersensitivity to irinotecan or any component of the formulation, in those with severe hepatic impairment, and in pregnant or breastfeeding women; caution is also advised for individuals with pre‑existing bowel disorders or uncontrolled infections.